Kenvue Inc. $KVUE Shares Acquired by Allstate Corp

Key Points

• Allstate Corp increased its holdings in Kenvue Inc. by 35.5% in the first quarter, owning 77,888 shares valued at approximately $1.87 million as of the latest SEC disclosure.
• Kenvue recently reported a quarterly earnings per share of $0.29, surpassing the consensus estimate, although its revenue declined 4% year-over-year to $3.84 billion.
• The company announced a quarterly dividend increase to $0.2075, with an annualized yield of 3.8%, despite a payout ratio of 112.16%.

Allstate Corp lifted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 35.5% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 77,888 shares of the company's stock after purchasing an additional 20,385 shares during the period. Allstate Corp's holdings in Kenvue were worth $1,868,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Compound Planning Inc. lifted its holdings in Kenvue by 38.5% during the 1st quarter. Compound Planning Inc. now owns 16,243 shares of the company's stock worth $390,000 after buying an additional 4,513 shares in the last quarter. Norinchukin Bank The increased its position in shares of Kenvue by 14.9% during the first quarter. Norinchukin Bank The now owns 97,754 shares of the company's stock worth $2,344,000 after acquiring an additional 12,690 shares during the period. Clarkston Capital Partners LLC increased its position in shares of Kenvue by 0.4% during the first quarter. Clarkston Capital Partners LLC now owns 1,370,403 shares of the company's stock worth $32,862,000 after acquiring an additional 4,820 shares during the period. CW Advisors LLC raised its stake in shares of Kenvue by 24.4% in the first quarter. CW Advisors LLC now owns 142,940 shares of the company's stock valued at $3,424,000 after acquiring an additional 27,991 shares in the last quarter. Finally, Candriam S.C.A. boosted its holdings in Kenvue by 19.9% in the first quarter. Candriam S.C.A. now owns 135,052 shares of the company's stock valued at $3,239,000 after purchasing an additional 22,425 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $21.5950 on Friday. The company has a market capitalization of $41.44 billion, a price-to-earnings ratio of 29.18, a price-to-earnings-growth ratio of 3.08 and a beta of 0.83. Kenvue Inc. has a 52-week low of $19.75 and a 52-week high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average price of $21.52 and a 200 day moving average price of $22.42.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion for the quarter, compared to analysts' expectations of $3.94 billion. During the same quarter last year, the company earned $0.32 earnings per share. The firm's revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be given a $0.2075 dividend. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 3.8%. Kenvue's payout ratio is currently 112.16%.

Analysts Set New Price Targets

Several research firms recently commented on KVUE. JPMorgan Chase & Co. lowered their target price on Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Royal Bank Of Canada decreased their price objective on Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. Citigroup cut their target price on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Bank of America reduced their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. Finally, Zacks Research upgraded shares of Kenvue to a "strong sell" rating in a report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.